06-Jan-2020 - Augustine Therapeutics

V-Bio Ventures invests in Augustine Therapeutics, a VIB and KU Leuven spin-off to fight neuromuscular diseases

V-Bio Ventures announced its investment in Augustine Therapeutics, a new venture developing innovative therapeutics for patients suffering from Charcot-Marie-Tooth disease. A spin-off of VIB and KU Leuven, Augustine raises a seed-round of 4.2 million euro with V-Bio Ventures, PMV, Advent France Biotechnology, Gemma Frisius Fund and VIB.

Augustine Therapeutics, a spin-off from VIB and KU Leuven, focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular diseases.  CMT is one of the most common hereditary disorders of the peripheral nervous system, affecting approximately 10 to 30 in 100,000 people globally. The disease is characterized by a progressive denervation of muscles, resulting in a slow decline of the patient’s day-to-day functioning. The current therapeutics market for CMT is limited to supportive management of symptoms.

The newly formed company is rooted in the ground-breaking research of the VIB-KU Leuven labs of Ludo Van Den Bosch and from a collaboration between the labs of Joris de Wit and Bart De Strooper (both VIB-KU Leuven).  According to Ludo Van Den Bosch: “We uncovered several biological pathways in peripheral neuropathies that represent promising therapeutic targets for CMT. The validation and in-depth study of the underlying biology of these targets now provides a first-rate foundation for the development of novel therapeutics.”

Augustine Therapeutics completes a seed financing round of 4.2 million euro. The company is the result of a collaborative effort of VIB, KU Leuven, V-Bio Ventures and PMV, joined by Advent France Biotechnology and Gemma Frisius Fund. Augustine Therapeutics is a great example of VIB’s approach to company co-creation with business partners and investors. In anticipation of attracting a dedicated management team for Augustine, the day-to day interim management of the company is assumed by Ward Capoen (V-Bio Ventures) and Jérôme Van Biervliet (VIB). 

More about Katholieke Universiteit Leuven
  • News

    From petroleum to wood

    An interdisciplinary team of bio-engineers and economists from KU Leuven has mapped out how wood could replace petroleum in the chemical industry. They not only looked at the technological requirements, but also whether that scenario would be financially viable. A shift from petroleum to wo ... more

    David Alsteens Receives 2019 Heinrich Emanuel Merck Award for Analytical Science

    Merck presented Professor David Alsteens (33), Catholic University of Louvain (UCLovain), Louvain-la-Neuve, Belgium with the 2019 Heinrich Emanuel Merck Award for Analytical Science. The award ceremony took place during the analytical conference Euroanalysis at Istanbul University in Turkey ... more

    New vulnerability found in major human viruses

    Discovery of a new feature of a large class of pathogenic viruses may allow development of new antiviral medications for the common cold, polio, and other illnesses, according to a new study publishing June 11 in the open-access journal PLOS Biology by Rana Abdelnabi and Johan Neyts of the ... more

More about Flanders Institute for Biotechnology
  • News

    Catching a tumor in a spider's web

    After a decade of research, the Belgian Switch Laboratory (VIB/KU Leuven) has revealed a new designer molecule that inhibits a well-validated cancer driver through the mechanism of amyloid formation. This work demonstrates that amyloid structures can be used to rationally develop a novel cl ... more

    New DNA sequencing nanopore

    VIB is proud to announce that the lab of Han Remaut (VIB/Vrije Universiteit Brussels) has teamed up with Oxford Nanopore Technologies for the development of nanopore sensing technology. VIB pioneered work on a protein nanopore, CsgG, which was developed into a sensing nanopore by Oxford Nan ... more

    Scientists learn how to predict plant size

    VIB and UGent scientists have developed a new method which allows them to predict the final size of a plant while it is still a seedling. Thanks to this method, which is based on the knowledge that a set of genes is associated with the final size of a leaf, scientists will be able to signif ... more

  • Research Institutes

    Flanders Institute for Biotechnology (VIB)

    VIB, the Flanders Institute for Biotechnology, is a non-profit scientific research institute. Using advanced gene technology, VIB studies the functioning of the human body, plants and microorganisms. VIB develops three complementary core activities: 1. Strategic basic research 2. An acti ... more

More about V-Bio Ventures
  • News

    Camel-IDS EUR 37m Series A financing led by V-Bio Ventures

    Camel-IDS, a VUB spin-off company developing cancer-targeted radiopharmaceuticals, today secured EUR 37m in a Series A investment round led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel) and BioMedP ... more